Approved by the U.S. Food and Drug Administration on April 11, 2016, Venclexta is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by a FDA approved test, who have received at least one prior therapy. The FDA approved this indication under accelerated approval based on overall response rate.
In the United States, CLL accounts for more than 14,000 newly diagnosed cases of leukemia each year. The 17p deletion is found in three to 10 percent of previously untreated cases and up to 30 to 50 percent of relapsed or refractory casesi. Venclexta provides a promising new treatment option for this high-risk subset of CLL patients.
“We are excited to help make this highly-anticipated treatment option available to patients in need,” said Shayne Malone, Vice President, Biopharma Services, Biologics, Inc. “We believe our team’s high-touch approach to patient care will accelerate access and help support the clinical, financial and emotional needs of this patient population.”
Biologics’ oncology specialty pharmacy is supported by a multidisciplinary care team that includes a financial counselor, pharmacist and oncology nurse. Individualized care plans are developed to address the unique needs of each patient and to streamline communication back to the treating provider.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
Biologics, Inc. is now part of McKesson Specialty Health, a division of McKesson Corporation. Our combined organization will help better support patients and expedite access to oncology therapies. Please continue to work with your dedicated sales representative and stay tuned for additional information on the integration.
About Biologics: Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.
i “AbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion,” AbbVie.com, April 11, 2016.